Quest Diagnostics (DGX) CCO sells 1,600 shares under 10b5-1 plan

Rhea-AI Filing Summary

Quest Diagnostics Inc. executive Mark E. Delaney, SVP & Chief Commercial Officer, reported selling 1,600 shares of common stock on 2026-07-28 at an average price of $235.18 per share. The sale was executed under a Rule 10b5-1 sales plan, and he now directly holds 10,335 shares.

Insider Trade Summary 10b5-1

Net Seller: 1,600 shares

Net Sell 1 txn

Insider DELANEY MARK E

Role SVP & Chief Commercial Officer

Sold 1,600 shs ($376K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,600	$235.18	$376K

Holdings After Transaction: Common Stock — 10,335 shares (Direct)

Footnotes (1)

1. F1. This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

Key Figures

Shares sold: 1600.0000 shares Sale price per share: $235.1800 per share Shares owned after sale: 10335.0000 shares

3 metrics

Shares sold 1600.0000 shares Common Stock sold on 2026-07-28 by Mark E. Delaney

Sale price per share $235.1800 per share Average price for the 1,600 shares of Common Stock sold

Shares owned after sale 10335.0000 shares Directly held Common Stock by Mark E. Delaney following the transaction

Key Terms

Rule 10b5-1 sales plan, Common Stock, open market or private transaction

3 terms

Rule 10b5-1 sales plan regulatory

"The sale was executed under a Rule 10b5-1 sales plan adopted by the reporting person"

Common Stock financial

"Mark E. Delaney reported selling 1,600 shares of Common Stock on 2026-07-28"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open market or private transaction market

"Transaction code S described as a sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/29/2026 - 05:05 PM Accepted by SEC EDGAR 07/29/2026 - 05:04 PM Learn about SEC filing dates

FAQ

What insider stock transaction did Quest Diagnostics (DGX) report?

Quest Diagnostics reported that Mark E. Delaney, SVP & Chief Commercial Officer, sold 1,600 shares of common stock on 2026-07-28 at $235.18 per share, leaving him with 10,335 shares directly owned.

Who at Quest Diagnostics (DGX) sold shares and what is their role?

Mark E. Delaney, who serves as SVP & Chief Commercial Officer of Quest Diagnostics, reported a sale of 1,600 shares of common stock, and after this transaction he directly owns 10,335 shares.

How many Quest Diagnostics (DGX) shares did Mark E. Delaney sell and at what price?

Mark E. Delaney sold 1,600 shares of Quest Diagnostics common stock at an average price of $235.18 per share. Following the transaction, his direct holdings total 10,335 shares.

Was the Quest Diagnostics (DGX) insider sale made under a Rule 10b5-1 plan?

Yes. The reported sale of 1,600 shares by Mark E. Delaney was executed under a Rule 10b5-1 sales plan adopted by the reporting person, indicating a pre-arranged trading plan.

How many Quest Diagnostics (DGX) shares does Mark E. Delaney own after the sale?

After selling 1,600 shares, Mark E. Delaney directly owns 10,335 shares of Quest Diagnostics common stock, as reported in the insider trading disclosure for the 2026-07-28 transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DELANEY MARK E

(Last) (First) (Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS INC

(Street)

SECAUCUS NEW JERSEY 07094

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2026		S(1)		1,600	D	$235.18	10,335	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

Remarks:

	Sean D. Mersten, Attorney in Fact for Mark E. Delaney	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)